TRAX · First Tracks Biotherapeutics Inc. Ordinary Shares
View on chartInsiders & Stakes
| EcoR1 Capital, LLC 10% Owner | ▼ Sell | Open Market | 3,174,519 Shares held | 4/20/2026 | View profile |
| John P. Schmid Director | ▲ Buy | Option Exercise | 37,652 Shares held | 6/15/2026 | View profile |
| Rita Jain | ▲ Buy | Option Exercise | 19,194 Shares held | 6/15/2026 | View profile |
| John A. Orwin Director | ▲ Buy | Option Exercise | 17,995 Shares held | 9/15/2026 | View profile |
| Magda Marquet Director | ▲ Buy | Option Exercise | 15,960 Shares held | 6/15/2026 | View profile |
| J. Anthony Ware | ▼ Sell | Open Market | 15,660 Shares held | 9/2/2026 | View profile |
| Dennis M. Fenton | ▲ Buy | Option Exercise | 10,995 Shares held | 6/15/2026 | View profile |
Transaction History
| John A. Orwin | ▲ Buy | Option Exercise | 1,300 | $0 | 9/15/2026 |
| J. Anthony Ware | ▲ Buy | Option Exercise | 39,265 | $225K | 9/2/2026 |
| J. Anthony Ware | ▼ Sell | Open Market | 39,265 | $1.8M | 9/2/2026 |
| Rita Jain | ▲ Buy | Option Exercise | 7,330 | $0 | 6/15/2026 |
| John P. Schmid | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2026 |
| John A. Orwin | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2026 |
| J. Anthony Ware | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2026 |
| Magda Marquet | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2026 |
| Dennis M. Fenton | ▲ Buy | Option Exercise | 6,030 | $0 | 6/15/2026 |
| EcoR1 Capital, LLC | ▼ Sell | Open Market | 4,705,575 | $65.0M | 4/20/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
TRAX Announces $200M Private Placement and Analyst Upgrades
First Tracks Biotherapeutics announced a $200 million private placement of shares at $32.75 each to institutional investors. Following this capital raise and recent trial data for ANB033, several firms including Leerink Partners, Evercore ISI, and Canaccord Genuity raised their price targets. The stock currently trades within its 52-week range, with an average analyst target of $74.17.
TRAX Announces $200M Private Placement and Analyst Upgrades. First Tracks Biotherapeutics announced a $200 million private placement of shares at $32.75 each to institutional investors. Following this capital raise and recent trial data for ANB033, several firms including Leerink Partners, Evercore ISI, and Canaccord Genuity raised their price targets. The stock currently trades within its 52-week range, with an average analyst target of $74.17.